CN109563046A - 组蛋白去乙酰酶6抑制剂及其用途 - Google Patents
组蛋白去乙酰酶6抑制剂及其用途 Download PDFInfo
- Publication number
- CN109563046A CN109563046A CN201780030151.3A CN201780030151A CN109563046A CN 109563046 A CN109563046 A CN 109563046A CN 201780030151 A CN201780030151 A CN 201780030151A CN 109563046 A CN109563046 A CN 109563046A
- Authority
- CN
- China
- Prior art keywords
- arh
- compound
- pharmaceutically acceptable
- acceptable salt
- quinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
Description
Claims (25)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662336863P | 2016-05-16 | 2016-05-16 | |
US62/336,863 | 2016-05-16 | ||
PCT/US2017/032784 WO2017200966A1 (en) | 2016-05-16 | 2017-05-16 | Histone deacetylase 6 inhibitors and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109563046A true CN109563046A (zh) | 2019-04-02 |
Family
ID=60326085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780030151.3A Pending CN109563046A (zh) | 2016-05-16 | 2017-05-16 | 组蛋白去乙酰酶6抑制剂及其用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US11427544B2 (zh) |
EP (1) | EP3458444B1 (zh) |
JP (1) | JP7083133B2 (zh) |
KR (1) | KR102518558B1 (zh) |
CN (1) | CN109563046A (zh) |
AU (1) | AU2017268184B2 (zh) |
TW (1) | TWI659949B (zh) |
WO (1) | WO2017200966A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112225737A (zh) * | 2020-12-11 | 2021-01-15 | 北京鑫开元医药科技有限公司 | 具有hdac抑制活性的化合物、制备方法、组合物及用途 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7292740B2 (ja) | 2017-09-08 | 2023-06-19 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Enpp1阻害剤及びがんの治療のためのそれらの使用 |
TWI807201B (zh) * | 2019-07-23 | 2023-07-01 | 臺北醫學大學 | 組蛋白去乙醯化酶6抑制劑及治療神經病變性疼痛的方法 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001038322A1 (en) * | 1999-11-23 | 2001-05-31 | Methylgene, Inc. | Inhibitors of histone deacetylase |
WO2003070691A1 (fr) * | 2002-02-21 | 2003-08-28 | Osaka Industrial Promotion Organization | Derive de n-hydroxycarboxamide |
WO2003087066A1 (en) * | 2002-04-11 | 2003-10-23 | Sk Chemicals, Co., Ltd. | α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS |
WO2004076386A2 (en) * | 2003-02-25 | 2004-09-10 | Topotarget Uk Limited | Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors |
CN1764648A (zh) * | 2003-01-13 | 2006-04-26 | 安斯泰来制药有限公司 | 作为组蛋白脱乙酰酶(hdac)抑制剂的异羟肟酸衍生物 |
JP2007001885A (ja) * | 2005-06-21 | 2007-01-11 | Univ Kansai | カルボキサミド誘導体 |
CN1901902A (zh) * | 2003-10-09 | 2007-01-24 | 阿托恩药品公司 | 噻吩和苯并噻吩异羟肟酸衍生物 |
WO2012106343A2 (en) * | 2011-02-01 | 2012-08-09 | The Board Of Trustees Of The University Of Illinois | Hdac inhibitors and therapeutic methods using the same |
WO2012120262A1 (en) * | 2011-03-09 | 2012-09-13 | Larsson Pia | Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors |
WO2015157504A1 (en) * | 2014-04-11 | 2015-10-15 | Taipei Medical University | Histone deacetylase inhibitors |
CN105358550A (zh) * | 2013-05-10 | 2016-02-24 | 卡鲁斯治疗有限公司 | 新型组蛋白脱乙酰基酶抑制剂 |
CN107531660A (zh) * | 2015-03-13 | 2018-01-02 | 福马治疗股份有限公司 | 作为HDAC8抑制剂的α‑肉桂酰胺化合物和组合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7135493B2 (en) * | 2003-01-13 | 2006-11-14 | Astellas Pharma Inc. | HDAC inhibitor |
US7781595B2 (en) * | 2003-09-22 | 2010-08-24 | S*Bio Pte Ltd. | Benzimidazole derivatives: preparation and pharmaceutical applications |
CA2542096A1 (en) * | 2003-10-09 | 2005-04-21 | Aton Pharma, Inc. | Thiophene and benzothiophene hydroxamic acid derivatives |
CN101255124B (zh) * | 2008-03-26 | 2010-06-02 | 山东大学 | 肉桂酰胺类组蛋白去乙酰化酶抑制剂及其制备方法 |
CN106414446A (zh) * | 2014-03-13 | 2017-02-15 | 新加坡科技研究局 | 基于稠合嘧啶的异羟肟酸盐衍生物 |
-
2017
- 2017-05-15 TW TW106115935A patent/TWI659949B/zh active
- 2017-05-16 KR KR1020187036499A patent/KR102518558B1/ko active IP Right Grant
- 2017-05-16 AU AU2017268184A patent/AU2017268184B2/en active Active
- 2017-05-16 WO PCT/US2017/032784 patent/WO2017200966A1/en unknown
- 2017-05-16 CN CN201780030151.3A patent/CN109563046A/zh active Pending
- 2017-05-16 EP EP17799969.5A patent/EP3458444B1/en active Active
- 2017-05-16 JP JP2018560157A patent/JP7083133B2/ja active Active
- 2017-05-16 US US16/302,021 patent/US11427544B2/en active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001038322A1 (en) * | 1999-11-23 | 2001-05-31 | Methylgene, Inc. | Inhibitors of histone deacetylase |
WO2003070691A1 (fr) * | 2002-02-21 | 2003-08-28 | Osaka Industrial Promotion Organization | Derive de n-hydroxycarboxamide |
WO2003087066A1 (en) * | 2002-04-11 | 2003-10-23 | Sk Chemicals, Co., Ltd. | α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS |
CN1764648A (zh) * | 2003-01-13 | 2006-04-26 | 安斯泰来制药有限公司 | 作为组蛋白脱乙酰酶(hdac)抑制剂的异羟肟酸衍生物 |
WO2004076386A2 (en) * | 2003-02-25 | 2004-09-10 | Topotarget Uk Limited | Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors |
CN1901902A (zh) * | 2003-10-09 | 2007-01-24 | 阿托恩药品公司 | 噻吩和苯并噻吩异羟肟酸衍生物 |
JP2007001885A (ja) * | 2005-06-21 | 2007-01-11 | Univ Kansai | カルボキサミド誘導体 |
WO2012106343A2 (en) * | 2011-02-01 | 2012-08-09 | The Board Of Trustees Of The University Of Illinois | Hdac inhibitors and therapeutic methods using the same |
WO2012120262A1 (en) * | 2011-03-09 | 2012-09-13 | Larsson Pia | Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors |
CN105358550A (zh) * | 2013-05-10 | 2016-02-24 | 卡鲁斯治疗有限公司 | 新型组蛋白脱乙酰基酶抑制剂 |
WO2015157504A1 (en) * | 2014-04-11 | 2015-10-15 | Taipei Medical University | Histone deacetylase inhibitors |
CN107531660A (zh) * | 2015-03-13 | 2018-01-02 | 福马治疗股份有限公司 | 作为HDAC8抑制剂的α‑肉桂酰胺化合物和组合物 |
Non-Patent Citations (5)
Title |
---|
SERGIO VALENTE ET AL.: "Novel Cinnamyl Hydroxyamides and 2-Aminoanilides as Histone Deacetylase Inhibitors: Apoptotic Induction and Cytodifferentiation Activity", 《CHEMMEDCHEM》 * |
TAISHI MAEDA ET AL.: "Inhibitory Effects of Cancer Cell Proliferation by Novel Histone Deacetylase Inhibitors Involve p21/WAF1 Induction and G2/M Arrest", 《BIOL. PHARM. BULL.》 * |
TAISHI MAEDA ET AL.: "Potent histone deacetylase inhibitors: N-hydroxybenzamides with antitumor activities", 《BIOORGANIC & MEDICINAL CHEMISTRY》 * |
XIAOYANG LI ET AL.: "Discovery of the First N ‑ Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity", 《J. MED. CHEM.》 * |
张万年: "《现代药物设计学》", 31 May 2006, 中国医药科技出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112225737A (zh) * | 2020-12-11 | 2021-01-15 | 北京鑫开元医药科技有限公司 | 具有hdac抑制活性的化合物、制备方法、组合物及用途 |
CN112225737B (zh) * | 2020-12-11 | 2021-04-09 | 北京鑫开元医药科技有限公司 | 具有hdac抑制活性的化合物、制备方法、组合物及用途 |
Also Published As
Publication number | Publication date |
---|---|
AU2017268184B2 (en) | 2021-04-01 |
JP7083133B2 (ja) | 2022-06-10 |
WO2017200966A1 (en) | 2017-11-23 |
JP2019521092A (ja) | 2019-07-25 |
AU2017268184A1 (en) | 2018-12-06 |
TW201805273A (zh) | 2018-02-16 |
TWI659949B (zh) | 2019-05-21 |
US11427544B2 (en) | 2022-08-30 |
KR102518558B1 (ko) | 2023-04-05 |
US20190284141A1 (en) | 2019-09-19 |
EP3458444A1 (en) | 2019-03-27 |
KR20190045093A (ko) | 2019-05-02 |
EP3458444A4 (en) | 2019-11-06 |
EP3458444B1 (en) | 2022-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9266872B2 (en) | 2-hydroxyarylamide derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating cancer containing same as active ingredient | |
WO2011069039A1 (en) | Hydrazone and diacyl hydrazine compounds and methods of use | |
CN109563046A (zh) | 组蛋白去乙酰酶6抑制剂及其用途 | |
JP6502919B2 (ja) | アミドピリジンオール誘導体またはその薬剤学的に許容可能な塩、及びそれを有効成分として含有する薬学組成物 | |
US20070099917A1 (en) | Novel inhibitors and methods for their preparation | |
TWI807201B (zh) | 組蛋白去乙醯化酶6抑制劑及治療神經病變性疼痛的方法 | |
DE112012004878T5 (de) | Heterocyclische Dihydro-Fünfring-Ketonderivate als DHODH-Inhibitor und ihre Verwendung | |
CN103547567A (zh) | 具有锌结合部分的刺猬蛋白拮抗剂 | |
WO2002076438A2 (en) | Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis | |
KR101630432B1 (ko) | 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용되는 염을 포함하는 암 예방 또는 치료용 약학 조성물 | |
NO326463B1 (no) | Kinolinderivater og sammensetninger omfattende nevnte derivater, samt anvendelser derav i medisinsk terapi, sa som ned behandling av kreft | |
Sadhasivam et al. | Synthesis, characterization, and anti-plasmodial activity of 2, 6-substituted benzothiazole derivatives | |
EP1844775B1 (en) | Therapeutic agent for the treatment of herpes progenitalis after development of lesions | |
EP4118069A1 (en) | 2,5- or 2,6-disubstituted hydroquinone derivatives with at least one carboxy, sulfo or amido group useful as medicaments | |
CN112920115A (zh) | 喹啉-4-甲酰胺类骨架衍生物及其用途 | |
CN114853670B (zh) | 含有酰胺基团的喹啉类化合物及其制备与应用 | |
JP6750177B2 (ja) | アントラニルアミド誘導体およびそれを含有するtlr3が関与する疾患の治療剤 | |
KR20180116966A (ko) | 신규 sirt 1 활성화제 및 이의 의학적 용도 | |
CN118063386A (zh) | (e)-n-[(1h-吲唑-7-基)甲基]-3-芳基丙烯酰胺衍生物的制备及其应用 | |
JPH03261783A (ja) | 1,2,4―トリアジンジオン化合物及びそれを有効成分とする抗コクシジウム剤 | |
WO2023055580A9 (en) | Benzylthiophene derivatives | |
CN114685496A (zh) | 基于异羟肟酸类hdac6抑制剂合成及其用途 | |
KR20180117068A (ko) | 신규 sirt 1 활성화제 및 이의 의학적 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20201012 Address after: Taipei City, Taiwan, China Applicant after: TAIPEI MEDICAL University Applicant after: National Taiwan University Address before: Taipei City, Taiwan, China Applicant before: TAIPEI MEDICAL University Effective date of registration: 20201012 Address after: Taipei City, Taiwan, China Applicant after: TAIPEI MEDICAL University Address before: Delaware, USA Applicant before: DCB-USA LLC |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220928 Address after: 250, Wuxing street, Xinyi District, Taipei, Taiwan, China Applicant after: TAIPEI MEDICAL University Applicant after: Yang Jiarong Address before: Taiwan, Taipei, China Applicant before: TAIPEI MEDICAL University Applicant before: National Taiwan University |